Flamel Technologies SA: Company Strategy, SWOT Analysis and 5-year Adjusted Financials

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 11-Jun-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Flamel Technologies is a drug delivery company focused on improving existing compounds using its Medusa and Micropump drug delivery technologies. The company entered into collaboration with Merck Serono in December 2007, to investigate the applicability of Flamel Technologies' Medusa technology for the extended release of a therapeutic protein of Merck Serono's portfolio.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    Flamel Technologies' Medusa platform product pipeline includes: IFN alpha-2b XL (Interferon alpha-2b XL) for hepatitis (Phase II), FT-105 for the treatment of type II diabetes (Phase I), IL-2 XL for the treatment of late stage renal cancer or metastatic melanoma (Phase I) and HGH XL used for the treatment of growth disorders (Preclinical).

    Flamel Technologies derives its revenues from the product sales of Coreg CR microparticles to GSK; and research and development, and license revenues from various pharmaceutical companies such as GSK and other undisclosed partners.

    Flamel Technologies's total revenues are expected to increase from $23 million in 2006 to $124 million in 2010. The company's major contributor to sales growth out to 2010 will be the royalties from GSK related to the product sales of Coreg CR which was approved in October 2006, for the treatment of cardiovascular diseases


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: swot analysis gsk merck flamel glaxosmithkline serono strategy sa xl

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.